Christopher C. Goodis

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 5 papers. Top paper: “Scaffold hopping from indoles to indazoles yields dual MCL-1/BCL-2 inhibitors from MCL-1 selective leads”.

Scaffold hopping from indoles to indazoles yields dual MCL-1/BCL-2 inhibitors from MCL-1 selective leads

RSC Medicinal Chemistry(2022)10.1039/d2md00095d

N/A

0DataRank · unranked

16 citations

Christopher C. Goodis, Nathan G. Bowen, Wenbo Yu, Gregory E.A. Vickers, Paul T. Wilder +3 more

Recent applications of covalent chemistries in protein–protein interaction inhibitors

RSC Medicinal Chemistry(2022)10.1039/d2md00112h

N/A

0DataRank · unranked

15 citations

Christopher C. Goodis, Elie G. Pommier, Steven Fletcher, Alexandria M. Chan

Multimodal nanoparticle‐containing modified suberoylanilide hydroxamic acid polymer conjugates to mitigate immune dysfunction in severe inflammation

Bioengineering & Translational Medicine(2023)10.1002/btm2.10611

N/A

0DataRank · unranked

9 citations

Andrea L. Cottingham, Shruti Dharmaraj, Jacob R. Shaw, Jackline Joy Lasola, Christopher C. Goodis +3 more

The polypharmacy combination of the BCL-2 inhibitor venetoclax (VEN) and the FLT3 inhibitor gilteritinib (GIL) is more active in acute myeloid leukemia cells than novel polypharmacologic BCL-2/FLT3 VEN–GIL hybrid single-molecule inhibitors

European Journal of Medicinal Chemistry(2024)10.1016/j.ejmech.2024.117190

N/A

0DataRank · unranked

7 citations

Christian Eberly, Alexandria M. Chan, Minjung Kim, Brandon D. Lowe, Curt I. Civin +2 more

Augmenting the Anti‐Leukemic Activity of the BCL‐2 Inhibitor Venetoclax Through Its Transformation Into Polypharmacologic Dual BCL‐2/HDAC1 and Dual BCL‐2/HDAC6 Inhibitors

Drug Development Research(2025)10.1002/ddr.70084

N/A

0DataRank · unranked

5 citations

Christian Eberly, Brandon Drennen, Christopher C. Goodis, Zoe Wuyts, Curt I. Civin +2 more